[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-380418-105":59,"doc-detail-380418-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","perioperative-immunotherapy-for-esophageal-squamous-cell-carcinoma-now-and-future","Perioperative immunotherapy for esophageal squamous cell carcinoma: Now and future","","Esophageal cancer ranks among the most prevalent malignant tumors of the digestive tract, and esophageal squamous cell carcinoma (ESCC) represents about 90% of cases. For clinical stage II–IVA locally advanced ESCC, standard care relies on neoadjuvant therapy plus surgical resection, yet long-term outcomes remain poor. Recent immunotherapy advances, particularly immune checkpoint inhibitors targeting PD-1/PD-L1, show encouraging responses and perioperative benefits. This review summarizes current perioperative immune checkpoint inhibitor use in resectable ESCC, highlights potential biomarkers, and discusses future perspectives.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/perioperative-immunotherapy-for-esophageal-squamous-cell-carcinoma-now-and-future/380418/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/perioperative-immunotherapy-for-esophageal-squamous-cell-carcinoma-now-and-future/380418.png","ImageObject",300,407,{"name":92,"@type":93},"Nguyễn Văn Học","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-24",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What does perioperative immunotherapy aim to improve in resectable ESCC?","Question",{"text":112,"@type":113},"It focuses on the role of immune checkpoint inhibitors during the perioperative period to improve clinical outcomes beyond standard neoadjuvant therapy and surgery.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Why are current treatments for locally advanced ESCC still considered inadequate?",{"text":117,"@type":113},"Even with neoadjuvant therapy and surgical resection, long-term outcomes are unsatisfactory, with poor prognoses and frequent local or systemic recurrence.",{"name":119,"@type":110,"acceptedAnswer":120},"Which immunotherapy targets are emphasized for advanced or metastatic ESCC?",{"text":121,"@type":113},"Monoclonal antibodies that inhibit programmed death 1 (PD-1) or programmed death ligand 1 (PD-L1) are highlighted for encouraging responses and perioperative benefits.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},380418,1790623610,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":56,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144},1374402739827,"https://ap-avatar.wpscdn.com/avatar/14000c97e7351f1a627?x-image-process=image/resize,m_fixed,w_180,h_180&k=1787885694763230660","| W | J | G | World Journal of\u003Cbr>Gastroenterology |\n| --- | --- | --- | --- |\n\nSubmit a Manuscript: [https://www.f6publishing.com](https://www.f6publishing.com) World J Gastroenterol 2023 September 14; 29(34): 5020-5037  \nDOI: 10.3748/wjg.v29.i34.5020 ISSN 1007-9327 (print) ISSN 2219-2840 (online)  \nREVIEW  \nPerioperative immunotherapy for esophageal squamous cell carcinoma: Now and future  \nYong Liu  \nSpecialty type: Gastroenterology and hepatology  \nProvenance and peer review:  \nInvited article; Externally peer reviewed.  \nPeer-review model: Single blind  \nPeer-review report’s scientific quality classification  \nGrade A (Excellent): A  \nGrade B (Very good): B  \nGrade C (Good): C  \nGrade D (Fair): 0  \nGrade E (Poor): 0  \nP-Reviewer: Matsuo Y, Japan; Nakano H, Japan; Viswanath Y, United Kingdom  \nReceived: April 23, 2023  \nPeer-review started: April 23, 2023  \nFirst decision: July 9, 2023  \nRevised: July 19, 2023  \nAccepted: August 15, 2023  \nArticle in press: August 15, 2023  \nPublished online: September 14, 2023  \nYong Liu, Department of Thoracic Surgery, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430011, Hubei Province, China  \nCorresponding author: Yong Liu, Doctor, MD, Chief Doctor, Surgeon, Surgical Oncologist, Department of Thoracic Surgery, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, No. 26 Shengli Street, Wuhan 430011, Hubei Province, [China.](China. liuyong7575@163.com)[ liuyong7575@163.com](China. liuyong7575@163.com)  \nAbstract  \nEsophageal cancer (EC) ranks among the most prevalent malignant tumors affecting the digestive tract. Esophageal squamous cell carcinoma (ESCC) stands as the prevailing pathological subtype, encompassing approximately 90% of all EC patients. In clinical stage II-IVA locally advanced ESCC cases, the primary approach to treatment involves a combination of neoadjuvant therapy and surgical resection. Despite concerted efforts, the long-term outcomes for ESCC patients remain unsatisfactory, with dismal prognoses. However, recent years have witnessed remarkable strides in immunotherapy, particularly in the secondand first-line treatment of advanced or metastatic ESCC, with the development of monoclonal antibodies that inhibit programmed death 1 or programmed death ligand 1 demonstrating encouraging responses and perioperative clinical benefits for various malignancies, including ESCC. This comprehensive review aims to present the current landscape of perioperative immunotherapy for resectable ESCC, focusing specifically on the role of immune checkpoint inhibitors during the perioperative period. Additionally, the review will explore promising biomarkers and offer insights into future prospects.  \nKey Words: Esophageal squamous cell carcinoma; Immune checkpoint inhibitors; Immunotherapy; Neoadjuvant; Randomized clinical trial  \n©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.  \n WJG  [https://www.wjgnet.com](https://www.wjgnet.com) 5020 September 14, 2023  Volume 29  Issue 34   \nLiu Y. Perioperative immunotherapy for ESCC  \nCore Tip: Esophageal cancer ranks among the most prevalent malignant tumors affecting the digestive tract. In locally advanced esophageal squamous cell carcinoma (ESCC), the mainstay of treatment involves neoadjuvant therapy in conjunction with surgical resection. Notably, immunotherapy has achieved significant breakthroughs in the second-and first-line treatment of advanced or metastatic ESCC. This review focuses on the current landscape of perioperative immunotherapy for resectable ESCC and discusses promising biomarkers and future perspectives.  \nCitation: Liu Y. Perioperative immunotherapy for esophageal squamous cell carcinoma: Now and future. World J Gastroenterol 2023;  \n29(34): 5020-5037  \nURL: [https://www.wjgnet.com/1007-9327/full/v29/i34/5020.htm](https://www.wjgnet.com/1007-9327/full/v29/i34/5020.htm)  \nD","cbCaifuCjQdCuHdL","https://ap.wps.com/l/cbCaifuCjQdCuHdL","pdf",519670,"English","# Abstract\n# Key Words\n# Core Tip\n# Introduction\n## Epidemiology and classification\n## Treatment overview: early vs locally advanced ESCC\n## Neoadjuvant therapy and surgery as a cornerstone","[{\"question\":\"What does perioperative immunotherapy aim to improve in resectable ESCC?\",\"answer\":\"It focuses on the role of immune checkpoint inhibitors during the perioperative period to improve clinical outcomes beyond standard neoadjuvant therapy and surgery.\"},{\"question\":\"Why are current treatments for locally advanced ESCC still considered inadequate?\",\"answer\":\"Even with neoadjuvant therapy and surgical resection, long-term outcomes are unsatisfactory, with poor prognoses and frequent local or systemic recurrence.\"},{\"question\":\"Which immunotherapy targets are emphasized for advanced or metastatic ESCC?\",\"answer\":\"Monoclonal antibodies that inhibit programmed death 1 (PD-1) or programmed death ligand 1 (PD-L1) are highlighted for encouraging responses and perioperative benefits.\"}]","Perioperative immunotherapy for esophageal squamous cell carcinoma: Now and future | PDF",1790240109,48]